Equites Radar

BRKR · Bruker Corporation

Medical DevicesUnited StatesAnalyst view: Buy

$53.43

-0.24% last session

End-of-day data · close of 2026-09-11

Neutral2 bullish · 2 bearish technical signals
Consensus: Buy (2.08 from 12 analysts)
To mean target: +9.7%

Market cap

$8B

Enterprise value

$10B

Trailing P/E

Forward P/E

22.3

Dividend yield

0.0%

Beta

1.26

Avg volume

2M

Employees

11K

Daily Change %

-0.24%

5 Days Change

-6.96%

10 Days Change

-6.17%

30 Days Change

-4.54%

60 Days Change

-9.37%

Month to Day Change

-2.86%

Year to Day Change

15.81%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)2.08
Covering analysts12
Mean price target$58.75
Low price target$40.00
Upside to mean target+9.7%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)40.3
50-day MA$58.31
200-day MA$48.18
Price vs 50-day MA-8.4%
Price vs 200-day MA+10.9%
MACD histogram-0.49
Volume vs 3-month avg1.0×
52w low $30.6852w high $64.34

Analyst sentiment over time — BRKR

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-09-09

Latest call per bank · past 12 months

UBS

Neutral

$65.00

+21.4% vs price
▲ raised from $45.00Maintains · 2026-09-09

Citigroup

Neutral

$53.00

-1.0% vs price
▼ cut from $60.00Maintains · 2026-08-05

Barclays

Overweight

$60.00

+12.0% vs price
▲ raised from $53.00Maintains · 2026-06-24

JP Morgan

Overweight

$65.00

+21.4% vs price
▲ raised from $55.00Maintains · 2026-06-08

Goldman Sachs

Sell

$35.00

-34.7% vs price
▼ cut from $40.00Maintains · 2026-02-13

Wells Fargo

Overweight

$55.00

+2.7% vs price
▲ raised from $48.00Maintains · 2025-12-15

Bank of America

Buy

$60.00

+12.0% vs price
▲ raised from $43.00Maintains · 2025-12-15

Recent rating actions

DateFirmActionRatingPrice target
2026-09-09UBSMaintainsNeutral$45.00 $65.00
2026-08-05CitigroupMaintainsNeutral$60.00 $53.00
2026-07-08CitigroupMaintainsNeutral$44.00 $60.00
2026-07-07Leerink PartnersMaintainsOutperform$60.00 $70.00
2026-06-29GuggenheimMaintainsBuy$50.00 $70.00
2026-06-24BarclaysMaintainsOverweight$53.00 $60.00
2026-06-08JP MorganMaintainsOverweight$55.00 $65.00
2026-05-07UBSMaintainsNeutral$40.00 $45.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-09-11

  • RSI (14): RSI is 40 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 8.4% below the 50-day MA ($58.31).
  • Price vs 200-day MA: Trading 10.9% above the 200-day MA ($48.18).
  • MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
  • MACD (12,26,9): MACD histogram is negative (-0.48) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($30.68) and high ($64.34).

BRKR Price Chart

Loading chart for BRKR

Fundamentals

Revenue (TTM)$3.0B
EBITDA$1.0B
Free cash flow$0M
Operating cash flow$0M
Book value / share$15.63
Net Debt / EBITDA3.1
WACC11.0%
Revenue growth5.00%
Earnings growth

About Bruker Corporation

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

More in Medical Devices

Screen BRKR against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.